Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Help Therapeutics to Start Trial of Universal Cell Therapy for Heart Failure

publication date: Jan 30, 2023

Beijing Help Therapeutics was approved to start China clinical trials of HiCM-188, a universal allogeneic iPS cell-derived cardiomyocyte therapy in patients with ischemic heart failure. It has already begun similar trials in Japan and Germany. The therapy consists of highly purified allogeneic cardiac muscle cells that are reprogrammed from human iPS cells. The transplanted cardiomyocytes are expected to couple electrically with the patient's myocardium to cause remuscularization. Founded in 2016, Help claims to be China’s first company to use induced pluripotent stem cells and mesenchymal stem cell technology to develop universal cell therapies for unmet needs in degenerative diseases. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital